DS 1093

Drug Profile

DS 1093

Alternative Names: DS-1093; DS-1093a

Latest Information Update: 04 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antianaemics
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Inflammatory bowel diseases

Highest Development Phases

  • Discontinued Anaemia

Most Recent Events

  • 27 Apr 2018 DS 1093 is available for licensing in European Union as of 04 May 2018. https://www.daiichisankyo.com
  • 29 Jan 2016 Discontinued - Phase-I for Anaemia in Hungary, United Kingdom, Hungary, Czech Republic (PO)
  • 01 Mar 2015 Daiichi Sankyo completes a phase I trial in Anaemia (in patients with chronic kidney disease) in Czech Republic and Hungary (NCT02299661)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top